Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“Teva UK has a track record of corporate misconduct.”
Mostly supportedConfidence: HIGH

Reasoning

The SEC press release confirms Teva Pharmaceutical Industries Ltd settled $519 million for FCPA violations involving bribes in Russia, Ukraine, and Mexico, indicating corporate misconduct. The Guardian article reports that the Royal College of Nursing cut ties with Teva UK citing the company's "track record of corporate misconduct," reinforcing the claim. Both sources are reliable and directly address misconduct by Teva, supporting the claim.

On confidence: Multiple independent sources document serious legal violations and public statements describing a history of misconduct.

Important context

The SEC settlement pertains to Teva Pharmaceutical Industries Ltd, the global parent, which includes its UK operations. The Guardian article specifically references Teva UK in the context of the RCN decision.

Evidence

Supporting (4)

Limitations

The evidence does not provide a comprehensive chronology of all misconduct incidents involving Teva UK; it highlights notable cases. No direct evidence of misconduct exclusive to the UK entity beyond the cited partnership termination is provided.

Last verified:
Oct 2, 2026, 4:09 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

Royal College of Nursing cuts ties with Israeli drug company

The Guardian · Denis Campbell Health policy editor